Hello, It’s a big day: Pfizer just said that its vaccine is more than 90% effective at preventing COVID-19, an incredibly important milestone in confronting the pandemic. Pfizer and its partner BioNTech are the first to report results on how effective a vaccine is, and it’s sending Pfizer’s stock â€” […]
Biogen plummeted 32% on Monday after the FDA Advisory Committee signalled that it is unconvinced Biogen’s Alzheimer’s therapy is effective in combating the disease. On Friday, the FDA AdCom voted 8-1 that data from the phase 3 EMERGE study evaluating Biogen’s aducanumab in patients with mild Alzheimer’s disease was not […]
Welcome to Business Insider ‘ s daily healthcare newsletter , your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday. Hello, I’m not sure what I thought election week was going to look like amid a pandemic, but I do […]
Welcome to Business Insider ‘ s daily healthcare newsletter , your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday. Hello, While we wait to hear more about the results of the presidential election, here’s the latest in healthcare news. […]
Biogen and Eisai said their experimental Alzheimer’s drug will be reviewed more quickly by regulators at the US Food and Drug Administration. If the drug is approved, it would be the first treatment to reduce the clinical decline of Alzheimer’s disease. The companies abandoned the drug in 2019, saying it […]
Morgan Stanley on Monday upgraded Biogen from underweight to overweight – a rare double upgrade – citing compelling risk versus reward in the long-term. The firm also boosted its price target on Biogen to $US357 from $US263. The new target price represents a more than 30% upside from where Biogen […]
Warren Buffett’s Berkshire Hathaway disclosed stakes in Kroger and Biogen on Friday. The famed investor spent about $US740 million on shares in the supermarket and biopharmaceuticals giants last quarter. News of the famed investor’s backing added $US2.5 billion to the pair’s combined market cap in after-hours trading. Kroger stock jumped […]
Hello, Welcome to Dispensed, Business Insider’s weekly healthcare newsletter, in which we’re keeping a close eye on One Medical stock price as it starts trading Friday after pricing at the bottom of its range last night. With earnings season in full swing, it’s been a busy week. Are you new […]
An experimental treatment for Alzheimer’s disease that was declared a failure in March has been brought back to life. Biotech giant Biogen and its partner Eisai plan to seek approval for the Alzheimer’s treatment, aducanumab, from the US Food and Drug Administration in 2020. In March, the drugmakers had stopped […]
Shares of Biogen surged more than 40% on Tuesday morning after the company announced plans to seek approval for an experimental Alzheimer’s treatment called aducanumab. Investors welcomed the news after the company’s shares plummeted 29% in March when Biogen said it would abandon the therapy following two failed clinical trials. […]
Biogen jumped about 2% in early trading on Tuesday after beating estimates and raising guidance for the rest of 2019. The company’s multiple sclerosis therapy led the company’s 72% revenue growth in the second quarter. The treatment brought in $US100 million more than analysts’ consensus estimate. The earnings beat comes […]
Biogen and the Japanese pharmaceutical company Eisai said Thursday they would discontinue late-stage Alzheimer’s drug trials. Shares of Biogen crashed more than 25% in pre-market trading. Watch Biogen trade live. Biogen shares crashed more than 25% in pre-market trading Thursday after the biotech company and Eisai, a Japanese pharmaceutical company, […]
Drugmakers Biogen and Eisai on Wednesday showed that the highest dose of their experimental Alzheimer’s drug, known as BAN2401, was able to slow the decline associated with Alzheimer’s by 30% compared to placebo. It’s the first time in years that the pharmaceutical industry has had a positive Alzheimer’s trial. The […]
Novartis is acquiring gene therapy company AveXis for $US8.7 billion. AveXis is working on a gene therapy for spinal muscular atrophy, a rare genetic condition that affects muscle movement in children and is the leading genetic cause of mortality in infants. It’s part of a wave of big bets in […]
(Reuters) - Biogen Inc's second-quarter profit...
The biggest biotech merger in years may be...
VIDEO: Jim Cramer, host of CNBC's Mad Money and co-founder of TheStreet.com, weighs in on the best and worst stocks for 2016.
Biogen is cutting 11% of its workforce, the...
Another one of Texan hedge fund manager J....
Biogen shares fell more than 16% in early...
« Previous Page